Bill & Melinda Gates Foundation-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bill & Melinda Gates Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011882
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bill & Melinda Gates Foundation (BMGF), formerly William H. Gates Foundation is a provider of health development programs. The foundation concentrates on improving healthcare, decrease poverty in America and provides access to information equipment. It offers global health services in the fields of discovery and translational sciences, enteric and diarrheal diseases, HIV, malaria, neglected infectious diseases, and tuberculosis services. BMGF’s global development services include agricultural development, family planning, emergency response, financial services for the poor, nutrition fulfillment, vaccine delivery, and water, sanitation and hygiene services. The foundation has its presence in Asia, Africa, Europe, North America, South America, and Oceania. BMGF is headquartered in Seattle, Washington, the US.

Bill & Melinda Gates Foundation – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2011 to YTD 2017 10
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Visterra Raises Additional USD23.6 Million in Series C Financing 13
Arsanis Raises USD45.5 Million in Series D Financing 15
Kymab Raises USD100.5 Million in Series C Financing 17
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 19
Affinivax Raises USD2.5 Million in Venture Financing 21
Lodo Therapeutics Raises USD17 Million in Series A Financing 22
Atreca Raises USD56 Million in Series A Financing 24
CureVac to Raise USD76 Million in Venture Financing 25
Affinivax Raises USD4 Million in Seed Venture Financing 26
Synlogic Raises Additional USD5 Million in Series A Venture Financing 27
Kymab Raises USD40 Million in Series B Financing 28
Visterra Raises US$8.1 Million In Extended Series A Financing 29
Visterra Raises Additional US$13 Million In Series A Financing 31
Genocea Biosciences Raises US$30 Million In Series C Financing 33
Partnerships 35
CureVac to Enter into Development Agreement with Bill & Melinda Gates 35
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 36
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 37
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 38
Atreca Enters into Agreement with Bill & Melinda Gates Foundation 39
Equity Offering 40
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 40
CureVac Raises USD110 Million in Private Placement of Shares 41
Bill & Melinda Gates Foundation – Key Competitors 42
Bill & Melinda Gates Foundation – Key Employees 43
Bill & Melinda Gates Foundation – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 44
Recent Developments 45
Government and Public Interest 45
Nov 29, 2017: Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin 45
Oct 23, 2017: Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year 46
Aug 18, 2017: IHI Partners with South Africa National Department of Health on Initiative to Improve Tuberculosis Care and Outcomes 47
Jun 12, 2017: Rotary and the Bill & Melinda Gates Foundation announce $450 million commitment to end polio 48
Mar 06, 2017: Vaxess Technologies Receives Grants Totaling $6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella 49
Jan 09, 2017: Kymab expands Infectious Disease Programmes 50
Dec 02, 2016: Access Bio recieved a USD $3.7 million grant from the Bill & Melinda Gates Foundation 51
Oct 19, 2016: Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection 52
Oct 18, 2016: Gates Foundation Awards $1.1 Million Grant for MediBeacon Collaboration with Washington University 53
Jun 09, 2016: Batavia Biosciences Receives Grant from the Bill & Melinda Gates Foundation to Support Vaccine Availability in Developing Count 54
May 26, 2016: EnBiotix, Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 55
Jan 18, 2016: Evestra Receives Gates Foundation Grant 56
Jan 12, 2016: Moderna Therapeutics, Through Valera, its Infectious Disease Venture, Announces Initial Grant of up to $20 Million to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection 57
Product News 58
Jul 20, 2016: Penn-led team develops plant-based Polio booster vaccine 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Key Facts 2
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bill & Melinda Gates Foundation, Deals By Therapy Area, 2011 to YTD 2017 9
Bill & Melinda Gates Foundation, Medical Devices Deals, 2011 to YTD 2017 10
Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Visterra Raises Additional USD23.6 Million in Series C Financing 13
Arsanis Raises USD45.5 Million in Series D Financing 15
Kymab Raises USD100.5 Million in Series C Financing 17
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 19
Affinivax Raises USD2.5 Million in Venture Financing 21
Lodo Therapeutics Raises USD17 Million in Series A Financing 22
Atreca Raises USD56 Million in Series A Financing 24
CureVac to Raise USD76 Million in Venture Financing 25
Affinivax Raises USD4 Million in Seed Venture Financing 26
Synlogic Raises Additional USD5 Million in Series A Venture Financing 27
Kymab Raises USD40 Million in Series B Financing 28
Visterra Raises US$8.1 Million In Extended Series A Financing 29
Visterra Raises Additional US$13 Million In Series A Financing 31
Genocea Biosciences Raises US$30 Million In Series C Financing 33
CureVac to Enter into Development Agreement with Bill & Melinda Gates 35
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 36
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 37
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 38
Atreca Enters into Agreement with Bill & Melinda Gates Foundation 39
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 40
CureVac Raises USD110 Million in Private Placement of Shares 41
Bill & Melinda Gates Foundation, Key Competitors 42
Bill & Melinda Gates Foundation, Key Employees 43
Bill & Melinda Gates Foundation, Other Locations 44
Bill & Melinda Gates Foundation, Joint Venture 44

★海外企業調査レポート[Bill & Melinda Gates Foundation-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Imperial Metals Corporation:企業の戦略・SWOT・財務情報
    Imperial Metals Corporation - Strategy, SWOT and Corporate Finance Report Summary Imperial Metals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • AECOM :企業の戦略・SWOT・財務情報
    AECOM - Strategy, SWOT and Corporate Finance Report Summary AECOM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • TE Connectivity Ltd (TEL):電力:M&Aディール及び事業提携情報
    Summary TE Connectivity Ltd (TE Connectivity), formerly Tyco Electronics Ltd, is a technology company. It designs and manufactures connectivity and sensor solutions. The company offers connectors; sensors; relays; heat shrink tubing; wire and cable; antennas and circuit protection devices. Its solut …
  • DeRoyal Industries Inc:医療機器:M&Aディール及び事業提携情報
    Summary DeRoyal Industries Inc (DeRoyal) is a medical device company that develops, manufactures and markets healthcare products. The company’s products portfolio includes surgical instruments and accessories, acute care products, patient protection products, orthopedics, rehabilitation products and …
  • Republic National Distributing Company:戦略・SWOT・企業財務分析
    Republic National Distributing Company - Strategy, SWOT and Corporate Finance Report Summary Republic National Distributing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Waterman Group Plc (WTM):企業の財務・戦略的SWOT分析
    Summary Waterman Group Plc (Waterman), formerly Waterman Partnership Holdings Plc, a subsidiary of CTI Engineering Co Ltd, is an engineering and environmental consultancy service provider that offers services for property, infrastructure, environment and energy markets. The company provides services …
  • Wanbury Ltd (WANBURY):企業の財務・戦略的SWOT分析
    Summary Wanbury Ltd (Wanbury) is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients. The company offers products such as Cpink tablet, rabiplus capsule, cdense tablets, gems, adtrol-plus soft gelatin capsule, folinine softule, cheer capsule and cheer syrup. It inc …
  • Babcock & Wilcox Enterprises Inc (BW):電力:M&Aディール及び事業提携情報
    Summary Babcock & Wilcox Enterprises, Inc. (Babcock & Wilcox) is a provider of technology-based advanced fossil and renewable power generation and environmental equipment. The company offers a range of biomass-fired boilers products such as supercritical boiler, waste-to-energy boilers, heat recover …
  • Gilead Sciences Inc (GILD)-製薬・医療分野:企業M&A・提携分析
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) in …
  • Tellurian Inc (TELL):石油・ガス:M&Aディール及び事業提携情報
    Summary Tellurian Inc (Tellurian), formerly Magellan Petroleum Corp, is an oil and gas company that provides exploration, development, and production of crude oil and natural gas. The company develops liquefied natural gas production and export terminal on the west bank of the Calcasieu River, south …
  • Pathway Genomics Corp-医療機器分野:企業M&A・提携分析
    Summary Pathway Genomics Corp (Pathway Genomics) is a healthcare laboratory that offers genetic testing services to physicians and their patients with actionable and accurate precision healthcare information to improve health and wellness. Its tests comprise liquid biopsy cancer intercept, true here …
  • Tyler Technologies Inc (TYL):企業の財務・戦略的SWOT分析
    Tyler Technologies Inc (TYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Outokumpu Oyj:企業の戦略・SWOT・財務情報
    Outokumpu Oyj - Strategy, SWOT and Corporate Finance Report Summary Outokumpu Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Russian Aircraft Corporation MiG JSC:企業の戦略・SWOT・財務情報
    Russian Aircraft Corporation MiG JSC - Strategy, SWOT and Corporate Finance Report Summary Russian Aircraft Corporation MiG JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Entergy New Orleans Inc:電力:M&Aディール及び事業提携情報
    Summary Entergy New Orleans Inc (Entergy) a subsidiary of Entergy Corporation is an electric utility company that offers power distribution services. The company provides electric distribution, account management, payment options and services, community services, business and economic development. I …
  • Ultra Clean Holdings Inc (UCTT):企業の財務・戦略的SWOT分析
    Summary Ultra Clean Holdings Inc (UCH) is a developer and supplier of critical systems and subsystems. The company’s products include precision robotic solutions, gas delivery systems, industrial and automation production equipment, chemical delivery modules, top-plate assemblies, wafer cleaning sub …
  • Tennessee Valley Authority:企業の戦略・SWOT・財務情報
    Tennessee Valley Authority - Strategy, SWOT and Corporate Finance Report Summary Tennessee Valley Authority - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Vitrolife AB (VITR):企業の財務・戦略的SWOT分析
    Summary Vitrolife AB (Vitrolife) is a developer, producer and marketer of laboratory products. The company provides products such as Oocyte retrieval needles, sperm processing, culture media, culture oil, additional culture media, micromanipulation solutions, vitrolife labware, micromanipulation pip …
  • Nova Scotia Power Inc:電力:M&Aディール及び事業提携情報
    Summary Nova Scotia Power Inc (NSP) a subsidiary of Emera Inc is a electric utility that provides electricity distribution services. The utility uses a fuel mix including hydro, tidal, wind, coal, oil, biomass and natural gas to generate electricity. It offers a range of home heating options, includ …
  • InSightec Ltd:製品パイプライン分析
    Summary Insightec Ltd (InSightec), a subsidiary of Elbit Imaging Ltd is a medical device company that develops and markets MR ultrasound based medical devices. The company offers products through divisions such as neurosurgery, oncology and womens’ health. It offers services including commercial dev …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆